Can Etrasimod-Velsipity cure ulcerative colitis and its clinical efficacy

Etrasimod-Velsipity is a new oral selective S1P receptor modulator, mainly used to treat patients with moderately to severely active ulcerative colitis (UC). The drug realizes the "redistribution" of lymphocytes from peripheral blood to lymph nodes by selectively regulating the S1P1 receptor, thereby reducing the infiltration of inflammatory cells into the intestinal mucosa, reducing the inflammatory response and alleviating intestinal symptoms. The mechanism of action of Itramod is different from that of traditional immunosuppressants or glucocorticoids. It does not directly kill inflammatory cells, but controls inflammation by regulating the function of the immune system. Therefore, it has shown good tolerability and long-term safety in clinical practice.

In terms of clinical efficacy, itrimod tablets cannot cure ulcerative colitis. UC is a chronic, relapsing autoimmune intestinal inflammatory disease for which there is no curative therapy. The main goals of treatment are to induce remission, maintain remission and improve quality of life. Itrimod has demonstrated significant efficacy in multiple pivotal clinical trials, including relieving intestinal symptoms, improving mucosal healing rates, and maintaining long-term remission. Studies have shown that compared with placebo, patients treated with itridimod can observe improvement in symptoms and increased mucosal healing rate under colonoscopy at week 12, and can also maintain a higher proportion of clinical remission rates during the maintenance period.

The efficacy of Itramod tablets is also reflected in its improvement in quality of life. UCPatients often suffer from abdominal pain, diarrhea, blood in the stool and other symptoms, which seriously affect their daily life and psychological state. Clinical trials have shown that long-term use of itramod can significantly improve patients' quality of life scores, including reducing symptom frequency, improving physical status and mental health. Because itridimod is an oral drug, it is easy to use and has high patient compliance. It has more advantages than intravenous injection or infusion treatment options.

Although itridimod has shown good efficacy, it is still necessary to pay attention to adverse reactions and safety during use. Common adverse reactions include headache, upper respiratory tract infection, increased liver enzymes, and mild to moderate decrease in heart rate. The patient's heart and liver function need to be assessed before taking the drug. Patients should regularly monitor hematological and biochemical indicators during treatment so that abnormalities can be detected in a timely manner and corresponding measures can be taken. For pregnant women or patients planning pregnancy, the risks should be assessed under the guidance of a physician.

In general, Etrasimod tablets (Etrasimod)-Velsipity cannot cure ulcerative colitis, but it has shown clear efficacy in inducing remission, maintaining remission and improving quality of life. Its selective S1P1 receptor modulation makes it UCNovel oral drug options for treatment. When using itrimod, patients should strictly follow the doctor's dosage and treatment instructions, combined with regular follow-up, symptom assessment and laboratory monitoring, to maximize the efficacy while ensuring safety. The drug provides an effective long-term management solution for patients with moderate to severe UCUC, but the cure still needs to wait for future research and more advanced treatments.

Reference:https://www.ema.europa.eu/en/medicines/human/EPAR/velsipity